Prevention Of Acute And Delayed Nausea And Vomiting With Highly Emetogenic Chemotherapy Therapeutics
1. Emend patent expiration
Treatment: Treatment or prevention of emesis; Prevention of postoperative nausea and vomiting
EMEND's oppositions filed in EPO
EMEND IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214692 | MSD | Medical use for tachykinin antagonists |
Sep, 2012
(13 years ago) | |
| US5538982 | MSD | Medical use for tachykinin antagonists |
Jul, 2013
(12 years ago) | |
| US5719147 | MSD | Morpholine and thiomorpholine tachykinin receptor antagonists |
Apr, 2015
(10 years ago) | |
| US6096742 | MSD | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(7 years ago) | |
| US8258132 | MSD | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 30 June, 2006
Dosage: CAPSULE
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
2. Emend patent expiration
Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)
EMEND's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6096742 | MSD MERCK CO | Polymorphic form of a tachykinin receptor antagonist |
Jul, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8258132 | MSD MERCK CO | Pharmaceutical composition of a tachykinin receptor antagonist |
Sep, 2027
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 17 December, 2015
Dosage: FOR SUSPENSION
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents
3. Emend patent
expiration
Treatment: Prevention or treatment of nausea or emesis induced by a cancer chemotherapeutic agent
EMEND IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5512570 | MERCK AND CO INC | Treatment of emesis with morpholine tachykinin receptor antagonists |
Mar, 2014
(11 years ago) | |
| US5538982 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Jul, 2013
(12 years ago) | |
| US7214692 | MERCK AND CO INC | Medical use for tachykinin antagonists |
Sep, 2012
(13 years ago) | |
| US5716942 | MERCK AND CO INC | Treatment of migraine with morpholine tachykinin receptor antagonists |
Feb, 2015
(10 years ago) | |
| US5691336 | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Mar, 2019
(6 years ago) | |
|
US5691336 (Pediatric) | MERCK AND CO INC | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
Sep, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2013 |
| M(M-82) | Mar 19, 2013 |
| New Dosing Schedule(D-128) | Nov 12, 2013 |
| New Patient Population(NPP) | Apr 03, 2021 |
| New Dosing Schedule(D-155) | Feb 01, 2019 |
| Pediatric Exclusivity(PED) | Oct 03, 2021 |
| New Dosing Schedule(D-186) | May 02, 2025 |
Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient
NCE-1 date: 03 October, 2020
Market Authorisation Date: 25 January, 2008
Dosage: POWDER
How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage
EMEND family patents